Merck & Co. stock sits at EUR 125.51, market cap USD 347.9 billion

Published on 10/08/2026 at 19:56 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Cantor lifted its target to USD 145.00 on October 8, 2026. Merck & Co. stock was EUR 125.51 on October 8, 2026 versus EUR 127.66, down 1.70 percent.

Key points in brief

Merck & Co. stock was at EUR 125.51 at Lang & Schwarz on October 8, 2026, down 1.70 percent versus EUR 127.66.
Cantor Fitzgerald kept a Neutral rating and raised its target from USD 120.00 to USD 145.00.
Merck reported Q2 2026 revenue of USD 16.61 billion, up 5.10 percent year over year.
Merck is scheduled to report third-quarter 2026 results on October 29, 2026.

Photorealistic wide-angle view of a modern oncology research laboratory. A scientist in white lab coat examines cancer cell slides under a fluorescence microscope. Amber glass vials with pharmaceutical compounds line the stainless steel bench. Biosafety c — Merck US58933Y1055 Onkologie-Labor: Wissenschaftler am Mikroskop analysiert Krebszellen, mehrere Wirkstoff-Vials stehen auf der Werkbank, Illustration mit AI erstellt.

Merck & Co. (ISIN US58933Y1055) stock sits at EUR 125.51 at Lang & Schwarz on October 8, 2026 at 7:45 p.m. CEST, down 1.70 percent versus the prior close of EUR 127.66. Cantor Fitzgerald analyst Carter Gould kept a Neutral rating and raised the price target from USD 120.00 to USD 145.00 on October 8, 2026, according to GuruFocus.

Price sits below the prior close

The euro quotation moved from EUR 127.66 to EUR 125.51 during the October 8 session, a decline of 1.70 percent on the Lang & Schwarz reference. The bid was EUR 125.50 and the ask EUR 125.52 at 7:45 p.m. CEST.

On the NYSE, Merck & Co. was last at USD 140.86 on October 8, 2026 at 1:55 p.m. ET, down USD 1.93 or 1.35 percent from USD 142.79. The 52-week range was USD 82.01 to USD 156.92, placing the U.S. quotation USD 16.06 below its high.

Second-quarter revenue grew 5.10 percent

Merck reported USD 16.61 billion in revenue for the second quarter of 2026, up 5.10 percent from USD 15.80 billion in the same quarter a year earlier, according to MarketBeat. The quarter also included diluted GAAP earnings per share of minus USD 0.54 and net income of minus USD 1.34 billion.

Comparison with peers

Merck & Co. (NYSE, USD): minus 1.70 percent, P/E 112.58, market capitalization USD 347.9 billion
Pfizer (NYSE, USD): minus 0.91 percent, P/E 36.67, market capitalization USD 158.1 billion
Bristol-Myers Squibb (NYSE, USD): minus 0.56 percent, P/E 13.07, market capitalization USD 121.3 billion

October 29 earnings date

Merck will hold its third-quarter 2026 sales and earnings conference call on October 29, 2026, at 9:00 a.m. ET, according to Merck. The date gives the market a defined next checkpoint after the second-quarter revenue increase and the latest target revisions.

Merck stock and the next checkpoint

The current market picture combines a EUR 125.51 Lang & Schwarz quotation with a USD 347.9 billion market capitalization and a USD 145.00 Cantor target. Cantor kept its Neutral view even after lifting the target, while Merck enters the October 29 reporting date with second-quarter revenue up 5.10 percent year over year. The further course of trading is shown by the continuously updated real-time quote of Merck & Co. stock.